Poor
Not Aligned
Patient Risk:
High
Summary
Several safety and contraindication claims are not supported by the provided label excerpts (e.g., seizure, depression/anxiety, bleeding-disorder contraindication, pancreatitis contraindication, and specific percentages for GI/other AEs). Some items are supported (mechanism, capsule form, FDA dosing description concept, and increased bleeding/AF risk), but multiple material inaccuracies prevent on-label alignment.
Category Scores
Accurate Statements
Vascepa is an omega-3 fatty acid medication.
Section 12.1 (EPA described as omega-3 fatty acid; “EPA reduces hepatic ... VLDL-TG ...”).
Vascepa reduces triglyceride production in the liver.
Section 12.1: “EPA reduces hepatic very low-density lipoprotein triglycerides (VLDL-TG) synthesis and/or secretion ...”.
Vascepa is available in capsule form.
Section 3: “VASCEPA capsules are supplied as ... soft-gelatin capsules ...”.
Vascepa is associated with an increased risk of cardiovascular events, including heart attack and stroke.
Not supported as stated; however the label excerpt includes risk reduction, not increased risk (see contradictions).
Unsupported Statements
Vascepa (icosapent ethyl) is a prescription medication used to lower triglyceride levels in adults with severe hypertriglyceridemia.
Partially supported: label includes reducing TG levels in adults with severe (≥500 mg/dL) hypertriglyceridemia (Section 1), but the statement additionally frames it as “lower triglyceride levels” without tying to the label’s specific indication wording; still consistent but not fully verifiable from excerpts alone.
Vascepa is typically taken once daily with a meal.
Contradicts provided dosing details in Section 2 (4 g/day taken as twice daily with food).
Abdominal pain occurs in up to 10% of patients taking Vascepa.
Specific GI adverse reaction incidence percentages (abdominal pain up to 10%) are not provided in the label excerpts (Section 6).
Diarrhea occurs in up to 9% of patients taking Vascepa.
Specific incidence percentages for diarrhea are not provided in the label excerpts (Section 6).
Nausea occurs in up to 8% of patients taking Vascepa.
Specific incidence percentages for nausea are not provided in the label excerpts (Section 6).
Vomiting occurs in up to 5% of patients taking Vascepa.
Specific incidence percentages for vomiting are not provided in the label excerpts (Section 6).
Constipation occurs in up to 4% of patients taking Vascepa.
Constipation is mentioned as a common adverse reaction (≥3% on Vascepa and ≥1% more frequent than placebo) in Section 6, but the specific “up to 4%” percentage is not provided in the excerpts.
Headache occurs in up to 3% of patients taking Vascepa.
No headache incidence percentage is provided in the label excerpts (Section 6).
Back pain occurs in up to 2% of patients taking Vascepa.
Musculoskeletal pain is listed as common (Section 6), but the specific “back pain up to 2%” is not provided.
Vascepa is associated with increased liver enzymes.
Hepatic impairment monitoring is mentioned (Section 8.7), but the label excerpts do not explicitly state that VASCEPA is “associated with increased liver enzymes” as an adverse reaction frequency/outcome.
Increased liver enzymes can be a sign of liver damage.
Not provided in the supplied label excerpts; this is interpretive and not supported by label text.
Vascepa is associated with an increased risk of cardiovascular events, including heart attack and stroke.
Label excerpts describe VASCEPA significantly reducing cardiovascular events (Section 14.1), not increasing them.
Vascepa is associated with seizures in rare cases.
Seizures are not mentioned in the provided label excerpts (Sections 5-6).
Vascepa is associated with psychiatric events, including depression and anxiety.
Depression/anxiety are not mentioned in the provided label excerpts (Sections 5-6).
Vascepa is contraindicated in patients with a history of bleeding disorders.
Provided contraindications excerpt (Section 4) is limited to hypersensitivity/anaphylaxis to VASCEPA/components; bleeding-disorder history contraindication not shown.
Vascepa is contraindicated in patients taking anticoagulant medications.
No contraindication for anticoagulants is stated in the provided contraindications excerpt (Section 4). Bleeding risk is discussed under warnings/precautions and drug interaction monitoring (Sections 5.3 and 7.1), not as a contraindication.
Vascepa is contraindicated in patients with a history of pancreatitis.
Contraindications excerpt (Section 4) does not mention pancreatitis. Additionally, Section 1 includes a “Limitations of Use” statement about pancreatitis risk not determined, not a contraindication.
Vascepa is contraindicated in patients taking medications that increase the risk of pancreatitis.
No such contraindication is present in the provided excerpts; only a limitation of use about pancreatitis risk determination is included (Section 1).
Vascepa can increase the risk of bleeding when taken with warfarin.
Section 5.3 states incidence of bleeding is greater with concomitant antithrombotic medications such as aspirin, clopidogrel, or warfarin, and Section 7.1 discusses monitoring with anticoagulants/antiplatelet agents. This is supported directionally, but the statement is not framed with label’s monitoring language; still, it is largely consistent (therefore not categorized as a contradiction).
Vascepa can increase the risk of bleeding when taken with anticoagulant medications.
Supported directionally by Section 5.3 and Section 7.1 (monitor for bleeding with concomitant anticoagulants/antiplatelet agents), but excerpt does not quantify magnitude for “increase risk”.
Vascepa can increase the risk of bleeding when taken with antiplatelet medications.
Supported directionally by Section 5.3 and Section 7.1 (monitor with concomitant antiplatelet agents).
Contradictions
High
AI Statement
Vascepa is typically taken once daily with a meal.
Label Reference
Section 2.2: daily dose 4 g/day taken as either four 0.5 g capsules twice daily with food or two 1 g capsules twice daily with food.
High
AI Statement
Vascepa is associated with an increased risk of cardiovascular events, including heart attack and stroke.
Label Reference
Section 14.1: “VASCEPA significantly reduced the risk” of cardiovascular composite endpoints including myocardial infarction and stroke.
High
AI Statement
Vascepa is contraindicated in patients taking anticoagulant medications.
Label Reference
Section 4 contraindications excerpt: only known hypersensitivity to VASCEPA/components. Bleeding risk is addressed as a warning/precaution (Section 5.3) and monitoring (Section 7.1), not as a contraindication.
Medium
AI Statement
Vascepa is contraindicated in patients taking medications that increase the risk of pancreatitis.
Label Reference
Section 1 Limitations of Use: effect on pancreatitis risk “has not been determined.” No contraindication for pancreatitis-risk medications shown; Section 4 does not list such contraindications.
Important Omissions
The AI response does not include the label’s specific indications (adjunct to maximally tolerated statin therapy to reduce risk of MI, stroke, coronary revascularization, and unstable angina hospitalization; and adjunct to diet for severe hypertriglyceridemia).
Importance:
Moderate
The AI response does not mention the label’s contraindication wording (known hypersensitivity/anaphylaxis to VASCEPA/components).
Importance:
Moderate
The AI response does not mention atrial fibrillation/flutter requiring hospitalization as a warning (Section 5.1).
Importance:
Moderate
The AI response does not mention the dosage form administration instruction to swallow capsules whole and not break/open/crush/dissolve/chew.
Importance:
Moderate
The AI response does not mention hepatic impairment monitoring (monitor ALT/AST periodically).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
High
Major label conflicts include dosing frequency (once daily vs twice daily with food) and incorrect directionality on cardiovascular event risk. Additional unsupported contraindications and unsubstantiated severe adverse events (seizures, depression/anxiety) further increase risk of misinformation.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Multiple direct contradictions to label dosing and cardiovascular risk direction; several contraindications and safety outcomes are unsupported by provided label excerpts.
Suggested Improvement
Use label excerpt wording: dose as 4 g/day twice daily with food (0.5 g caps QD-BID or 1 g caps BID), state indication(s) accurately, restrict contraindications to known hypersensitivity to VASCEPA/components, and describe bleeding as an increased risk with concomitant antithrombotic therapy with monitoring rather than listing false contraindications.